Literature DB >> 29587554

Irreversible profound symptomatic bradycardia requiring pacemaker after tizanidine/loxoprofen combination therapy: a case report.

Xiaolin Li1, Yunpeng Jin2.   

Abstract

A 37-year-old man suffered irreversible profound symptomatic bradycardia requiring a pacemaker 3 days after beginning tizanidine/loxoprofen combination therapy for neck pain. This combination therapy is prescribed frequently for joint pain; however, combining loxoprofen with tizanidine could increase the risk of symptomatic bradycardia that is both permanent and severe. Similar cases have not been reported. This case suggests that tizanidine should be used cautiously when combined with loxoprofen, and drug interaction screening should be performed.

Entities:  

Keywords:  Case report; bradycardia; loxoprofen; pacemaker; side effect; tizanidine

Mesh:

Substances:

Year:  2018        PMID: 29587554      PMCID: PMC6023050          DOI: 10.1177/0300060518765009

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Introduction

Tizanidine, an α2-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity and pain.[1] However, adverse events have been reported with its use, including somnolence, dry mouth, asthenia, and dizziness.[2-4] Bradycardia is among the reported events following tizanidine overdose.[5] There are only rare reports of bradycardia as a side effect of tizanidine at conventional doses.[6,7] In those cases, the heart rate improved after tizanidine was stopped. Another report describes a 93-year-old woman with irreversible profound symptomatic bradycardia from tizanidine.[8] Here we report the case of a man who experienced irreversible profound symptomatic bradycardia requiring pacemaker placement after tizanidine/loxoprofen combination therapy.

Case report

A 37-year-old man with the chief complaints of profound dyspnea and dizziness for 3 days was admitted to the hospital with blood pressure 130/66 mmHg and heart rate 42 beats per minute. He was previously healthy and had been taking no other medications. His personal history and family history were unremarkable; specifically, he had no family history of heart disease. Three days before hospital admission, he had been seen at a pain clinic and was started on tizanidine and loxoprofen for neck pain. After taking an 18-mg total dose of tizanidine and 300 mg of loxoprofen, the patient developed severe symptomatic bradycardia. At admission, his oxygen saturation was normal, and an electrocardiogram revealed third-degree atrioventricular block with a heart rate of 42 beats per minute (Figure 1). His echocardiogram was normal. Laboratory testing revealed elevated triglycerides at 2.72 mmol/L. Troponin T and CK-MB were negative both at admission and 6 hours later. Tizanidine and loxoprofen were withheld, and IV fluids were administered upon admission. Cardiac catheterization was performed with no abnormal finding, and a transvenous pacer was placed immediately. During the next few days, his heart rate improved only slightly. Before discharge, the patient received a dual-chamber pacemaker for continued severe symptomatic bradycardia. After receiving the pacemaker, an electrocardiogram (Figure 2) and Holter electrocardiogram (Figure 3) revealed continuous paced rhythm.
Figure 1.

Electrocardiogram before pacemaker.

Figure 2.

Electrocardiogram after pacemaker.

Figure 3.

Holter electrocardiogram after pacemaker.

Electrocardiogram before pacemaker. Electrocardiogram after pacemaker. Holter electrocardiogram after pacemaker. The study protocol was approved by the Ethics Committee of The Fourth Affiliated Hospital of Zhejiang University School of Medicine. The patient provided written informed consent for this case report.

Discussion

The usual causes of bradycardia such as electrolyte disorders, intracranial pressure elevation, hypothyroidism, infection, hypothermia, hyperactive carotid sinus reflex, organic heart disease, and pharmacotherapy with digitalis, beta-blockers and antiarrhythmics were excluded in this case. Bradycardia as a side effect of tizanidine has been reported.[5-7] In such cases, the heart rate improved after tizanidine was stopped. The heart rate of this adult patient barely improved despite cessation of tizanidine. It is possible that the severe permanent bradycardia experienced by this patient resulted solely from tizanidine; however, tizanidine/loxoprofen combination therapy could be the cause. A case involving the interaction of tizanidine combined with rofecoxib has been reported.[7] Tizanidine is mainly metabolized by cytochrome P450;[9] loxoprofen inhibits this enzyme,[10] so an interaction between these drugs is possible. Irreversible profound symptomatic bradycardia has never been reported as a side effect of loxoprofen; however, palpitations may occur with oral loxoprofen.[11] The cardiac electrophysiological properties of tizanidine and loxoprofen have yet to be clarified. Thus, it should be considered that the combined use of tizanidine and loxoprofen increases the risk of tizanidine-associated irreversible profound symptomatic bradycardia. Irreversible profound symptomatic bradycardia requiring pacemaker placement after using tizanidine/loxoprofen combination therapy has not been reported. Through this case, we believe that tizanidine should be used cautiously when combined with loxoprofen and drug interaction screening should be performed.
  11 in total

1.  Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.

Authors:  K Iwasaki; H Matsuda; K Nagase; T Shiraga; Y Tokuma; K Uchida
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-11

2.  [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].

Authors:  Anastas Kick; Raffaela Bertoli; Giorgio Moschovitis; Pia Caduff Janosa; Andreas Cerny
Journal:  Med Klin (Munich)       Date:  2005-04-15

3.  Profound symptomatic bradycardia requiring transvenous pacing after a single dose of tizanidine.

Authors:  Jennifer Cortes; Brad Hall; Danyelle Redden
Journal:  J Emerg Med       Date:  2014-11-20       Impact factor: 1.484

4.  Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy.

Authors:  Susan W Publow; Donald L Branam
Journal:  Am J Health Syst Pharm       Date:  2010-10-01       Impact factor: 2.637

Review 5.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 6.  Loxoprofen: A Review in Pain and Inflammation.

Authors:  Sarah L Greig; Karly P Garnock-Jones
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.

Authors: 
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

8.  Mechanisms of tizanidine action on spasticity.

Authors:  I Milanov; D Georgiev
Journal:  Acta Neurol Scand       Date:  1994-04       Impact factor: 3.209

9.  Retrospective review of Tizanidine (Zanaflex) overdose.

Authors:  Henry A Spiller; George M Bosse; Larry A Adamson
Journal:  J Toxicol Clin Toxicol       Date:  2004

10.  Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.

Authors:  Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

View more
  1 in total

1.  Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators.

Authors:  Sanjita Paudel; Aarajana Shrestha; Piljoung Cho; Riya Shrestha; Younah Kim; Taeho Lee; Ju-Hyun Kim; Tae Cheon Jeong; Eung-Seok Lee; Sangkyu Lee
Journal:  Pharmaceutics       Date:  2019-09-16       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.